The lipoprotein lipase (LPL) gene encodes a rate-limiting enzyme protein that has a key role in the hydrolysis of triglycerides. Hypertriglyceridemia, one widely prevalent syndrome of LPL deficiency ...

Determination of Activity of Lipoprotein Lipase Activity was measured by the amount of free fatty acids released by control or postheparin plasma from an artificial lipoprotein triglyceride substrate ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 87, No. 3 (1990), pp. 909-913 (5 pages) Lipoprotein lipase (LPL) catalyzes the flux-generating step in transport ...

Although able to hydrolyze a coconut-oil emulsion, the postheparin plasma of a patient with fat-induced (Type 5) hyperlipemia was unable to hydrolyze his own, normal human or rat chylomicrons.

In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn ...

Kathryn H. Gunn, Benjamin S. Roberts, Fengbin Wang, Joshua D. Strauss, Mario J. Borgnia, Edward H. Egelman, Saskia B. Neher Proceedings of the National Academy of ...

A new study published in the Journal American Medical Association showed that low-molecular-weight heparin (LMWH) might not ...

Objective: To study the effect of oral oleoyl-estrone on the plasma lipoprotein profile and tissue lipase activities in order to determine the handling of circulating lipids by adipose tissue, liver ...

During the first 18 months after treatment with ali-pogene tiparvovec, a gene therapy recently approved in Europe to treat lipoprotein lipase deficiency (LPLD), the first patient to receive the ...

Over a 6-year period, patients with the genetic disease lipoprotein lipase deficiency (LPLD) who received a single gene therapy treatment of alipogene tiparvovec had a marked reduction in the severity ...

The first patient who received the gene therapy that was recently approved in Europe to treat lipoprotein lipase deficiency (LPLD) had no abdominal pain or episodes of pancreatitis, following a ...

In a Phase III clinical trial, the drug volanesorsen significantly reduced blood fat (triglyceride) levels in participants with a rare disease called familial chylomicronemia syndrome; finding could ...